BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma · Portal Vein Tumor Thrombus · Oligometastases · Radiotherapy · Immunotherapy · Hepatic Artery Infusion Chemotherapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Contact: Study coordinator (Jinbo Yue, doctor) · jbyue@sdfmu.edu.cn · 0531-67626442
Contact: Study coordinator (Jinbo Yue, Doctor) · jbyue@sdfmu.edu.cn

Study leads

Jinbo Yue, Doctor
Principal Investigator
Shandong Cancer Hospital and Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma · Chemotherapy · Stereotactic Body Radiotherapy

Abroad (travel likely)Recruiting

Yongin-si, South Korea

Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma

Hepatocellular Carcinoma · Immunotherapy

Abroad (travel likely)Recruiting

Hangzhou, China

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma · Conversion Therapy

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases · Hepatocellular Carcinoma · Immunotherapy

Abroad (travel likely)Recruiting

Guanzhou, China